Biology of Barrett's Esophagus and Esophageal Adenocarcinoma

Gastrointestinal Endoscopy Clinics of North America

Volumn 21, Issue 1, 2011, Pages 25-38

  Wang, David H ^a,b,c   Souza, Rhonda F ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Barrett's esophagus; Esophageal adenocarcinoma; Metaplasia

Indexed keywords

PROTEIN P16; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TELOMERASE; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SOX9;

BARRETT ESOPHAGUS; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL CYCLE; DISEASE ASSOCIATION; DNA SYNTHESIS; DYSPLASIA; EMBRYO DEATH; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HISTOPATHOLOGY; MITOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SENESCENCE; STEM CELL;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION;

EID: 78649566049     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.giec.2010.09.011     Document Type: Review

References (83)

1. Jemal A., Thun M.J., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100(23):1672-1694.
2. Demeester S.R. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res 2009, 3(Suppl 2):S2-S5.
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
4. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103(3):788-797.
5. Dulai G.S., Guha S., Kahn K.L., et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002, 122(1):26-33.
6. Souza R.F. A molecular rationale for the how, when and why of colorectal cancer screening. Aliment Pharmacol Ther 2001, 15(4):451-462.
7. Spechler S.J. Clinical practice. Barrett's esophagus. N Engl J Med 2002, 346(11):836-842.
8. Tosh D., Slack J.M. How cells change their phenotype. Nat Rev Mol Cell Biol 2002, 3(3):187-194.
9. Guillem P.G. How to make a Barrett esophagus: pathophysiology of columnar metaplasia of the esophagus. Dig Dis Sci 2005, 50(3):415-424.
10. Johns B.A. Developmental changes in the oesophageal epithelium in man. J Anat 1952, 86(4):431-442.
11. Yu W.Y., Slack J.M., Tosh D. Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. Dev Biol 2005, 284(1):157-170.
12. Sawhney R.A., Shields H.M., Allan C.H., et al. Morphological characterization of the squamocolumnar junction of the esophagus in patients with and without Barrett's epithelium. Dig Dis Sci 1996, 41(6):1088-1098.
13. Sancho E., Batlle E., Clevers H. Signaling pathways in intestinal development and cancer. Annu Rev Cell Dev Biol 2004, 20:695-723.
14. Daniely Y., Liao G., Dixon D., et al. Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. Am J Physiol Cell Physiol 2004, 287(1):C171-C181.
15. Glickman J.N., Yang A., Shahsafaei A., et al. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 2001, 32(11):1157-1165.
16. Leedham S.J., Preston S.L., McDonald S.A., et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 2008, 57(8):1041-1048.
17. Colleypriest B.J., Palmer R.M., Ward S.G., et al. Cdx genes, inflammation and the pathogenesis of Barrett's metaplasia. Trends Mol Med 2009, 15(7):313-322.
18. Epperly M.W., Guo H., Shen H., et al. Bone marrow origin of cells with capacity for homing and differentiation to esophageal squamous epithelium. Radiat Res 2004, 162(3):233-240.
19. Sarosi G., Brown G., Jaiswal K., et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus 2008, 21(1):43-50.
20. Korbling M., Katz R.L., Khanna A., et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 2002, 346(10):738-746.
21. Wong N.A., Wilding J., Bartlett S., et al. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A 2005, 102(21):7565-7570.
22. Moons L.M., Bax D.A., Kuipers E.J., et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004, 57(10):1063-1068.
23. Wang D.H., Clemons N.J., Miyashita T., et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 2010, 138(5):1810-1822.
24. Chan C.W., Wong N.A., Liu Y., et al. Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc Natl Acad Sci U S A 2009, 106(6):1936-1941.
25. Traber P.G., Wu G.D., Wang W. Novel DNA-binding proteins regulate intestine-specific transcription of the sucrase-isomaltase gene. Mol Cell Biol 1992, 12(8):3614-3627.
26. Silberg D.G., Swain G.P., Suh E.R., et al. Cdx1 and cdx2 expression during intestinal development. Gastroenterology 2000, 119(4):961-971.
27. Gao N., White P., Kaestner K.H. Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. Dev Cell 2009, 16(4):588-599.
28. Mutoh H., Sakurai S., Satoh K., et al. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut 2004, 53(10):1416-1423.
29. Phillips R.W., Frierson H.F., Moskaluk C.A. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003, 27(11):1442-1447.
30. Groisman G.M., Amar M., Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004, 17(10):1282-1288.
31. Eda A., Osawa H., Satoh K., et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003, 38(1):14-22.
32. Blache P., van de Wetering M., Duluc I., et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004, 166(1):37-47.
33. Bastide P., Darido C., Pannequin J., et al. Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J Cell Biol 2007, 178(4):635-648.
34. Burnat G., Rau T., Elshimi E., et al. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Scand J Gastroenterol 2007, 42(12):1460-1465.
35. Marchetti M., Caliot E., Pringault E. Chronic acid exposure leads to activation of the cdx2 intestinal homeobox gene in a long-term culture of mouse esophageal keratinocytes. J Cell Sci 2003, 116(Pt 8):1429-1436.
36. Liu T., Zhang X., So C.K., et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis 2007, 28(2):488-496.
37. Hu Y., Jones C., Gellersen O., et al. Pathogenesis of Barrett esophagus: deoxycholic acid up-regulates goblet-specific gene MUC2 in concert with CDX2 in human esophageal cells. Arch Surg 2007, 142(6):540-544. [discussion: 544-5].
38. Tatsuta T., Mukaisho K., Sugihara H., et al. Expression of Cdx2 in early GRCL of Barrett's esophagus induced in rats by duodenal reflux. Dig Dis Sci 2005, 50(3):425-431.
39. Huo X., Zhang H.Y., Zhang X.I., et al. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. Gastroenterology 2010, 139(1):194-203. e1.
40. van de Wetering M., Sancho E., Verweij C., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111(2):241-250.
41. Lickert H., Domon C., Huls G., et al. Wnt/(beta)-catenin signaling regulates the expression of the homeobox gene Cdx1 in embryonic intestine. Development 2000, 127(17):3805-3813.
42. Bian Y.S., Osterheld M.C., Bosman F.T., et al. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000, 114(4):583-590.
43. Fre S., Huyghe M., Mourikis P., et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005, 435(7044):964-968.
44. Stanger B.Z., Datar R., Murtaugh L.C., et al. Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci U S A 2005, 102(35):12443-12448.
45. van Es J.H., van Gijn M.E., Riccio O., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435(7044):959-963.
46. Sander G.R., Powell B.C. Expression of notch receptors and ligands in the adult gut. J Histochem Cytochem 2004, 52(4):509-516.
47. Morrow D.J., Avissar N.E., Toia L., et al. Pathogenesis of Barrett's esophagus: bile acids inhibit the Notch signaling pathway with induction of CDX2 gene expression in human esophageal cells. Surgery 2009, 146(4):714-721. [discussion: 721-2].
48. Menke V., van Es J.H., de Lau W., et al. Conversion of metaplastic Barrett's epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis Model Mech 2010, 3(1-2):104-110.
49. Que J., Choi M., Ziel J.W., et al. Morphogenesis of the trachea and esophagus: current players and new roles for noggin and Bmps. Differentiation 2006, 74(7):422-437.
50. Milano F., van Baal J.W., Buttar N.S., et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 2007, 132(7):2412-2421.
51. Litingtung Y., Lei L., Westphal H., et al. Sonic hedgehog is essential to foregut development. Nat Genet 1998, 20(1):58-61.
52. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
53. Hahn W.C., Weinberg R.A. Rules for making human tumor cells. N Engl J Med 2002, 347(20):1593-1603.
54. Colotta F., Allavena P., Sica A., et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30(7):1073-1081.
55. Huang Y., Meltzer S.J., Yin J., et al. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res 1993, 53(8):1889-1894.
56. Coppola D., Schreiber R.H., Mora L., et al. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncol 1999, 6(3):298-304.
57. Klump B., Hsieh C.J., Holzmann K., et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998, 115(6):1381-1386.
58. Wong D.J., Barrett M.T., Stoger R., et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997, 57(13):2619-2622.
59. Maley C.C., Galipeau P.C., Li X., et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004, 64(20):7629-7633.
60. Younes M., Lebovitz R.M., Lechago L.V., et al. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993, 105(6):1637-1642.
61. Hamelin R., Flejou J.F., Muzeau F., et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994, 107(4):1012-1018.
62. Ramel S., Reid B.J., Sanchez C.A., et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992, 102(4 Pt 1):1220-1228.
63. Malumbres M., Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci 1998, 3:d887-d912.
64. Inamdar G.S., Madhunapantula S.V., Robertson G.P. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol 2010, 80(5):624-637.
65. Cooper G.M. Cellular transforming genes. Science 1982, 217(4562):801-806.
66. Meltzer S.J., Mane S.M., Wood P.K., et al. Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. Cancer Res 1990, 50(12):3627-3630.
67. Lord R.V., O'Grady R., Sheehan C., et al. K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol 2000, 15(7):730-736.
68. Sommerer F., Vieth M., Markwarth A., et al. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 2004, 23(2):554-558.
69. Abdelatif O.M., Chandler F.W., Mills L.R., et al. Differential expression of c-myc and H-ras oncogenes in Barrett's epithelium. A study using colorimetric in situ hybridization. Arch Pathol Lab Med 1991, 115(9):880-885.
70. Jankowski J., McMenemin R., Hopwood D., et al. Abnormal expression of growth regulatory factors in Barrett's oesophagus. Clin Sci (Lond) 1991, 81(5):663-668.
71. Auvinen M.I., Sihvo E.I., Ruohtula T., et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002, 20(13):2971-2979.
72. Lord R.V., Park J.M., Wickramasinghe K., et al. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003, 125(2):246-253.
73. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33(5):787-791.
74. Morales C.P., Lee E.L., Shay J.W. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998, 83(4):652-659.
75. Lord R.V., Salonga D., Danenberg K.D., et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000, 4(2):135-142.
76. Abdel-Latif M.M., O'Riordan J., Windle H.J., et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004, 239(4):491-500.
77. O'Riordan J.M., Abdel-latif M.M., Ravi N., et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005, 100(6):1257-1264.
78. Dvorak K., Chavarria M., Payne C.M., et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to Barrett's esophagus. Clin Cancer Res 2007, 13(18 Pt 1):5305-5313.
79. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295(5564):2387-2392.
80. Herszenyi L., Hritz I., Pregun I., et al. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol 2007, 13(5):676-682.
81. Murray G.I., Duncan M.E., O'Neil P., et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998, 185(3):256-261.
82. Salmela M.T., Karjalainen-Lindsberg M.L., Puolakkainen P., et al. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001, 85(3):383-392.
83. Haura E.B., Turkson J., Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005, 2(6):315-324.